New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage ...